国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (3): 214-217.doi: 10.3760/cma.j.issn.1673422X.2015.03.013

• 综述 • 上一篇    下一篇

肺癌免疫治疗临床试验进展

刘皓, 高红军   

  1. 100071北京，中国人民解放军第307医院造血干细胞移植科（刘皓），肺部肿瘤内科（高红军）；上海恒润生物研究所（刘皓）
  • 出版日期:2015-03-08 发布日期:2015-01-29
  • 通讯作者: 高红军，Email:gaohj6708@hotmail.com E-mail:gaohj6708@hotmail.com

Progress of immunotherapy trials in the treatment of lung cancer

Liu Hao, Gao Hongjun   

  1. Department of Hematopoietic Stem Cell Transplantation, PLA No.307 Hospital, Beijing 100071, China; Shanghai Hengrun Institute of Biology, Shanghai 200030, China
  • Online:2015-03-08 Published:2015-01-29
  • Contact: Gao Hongjun E-mail:gaohj6708@hotmail.com

PDF

1253

被引次数

1

摘要： 手术联合放化疗是肺癌常规治疗手段，但术后复发十分常见，患者死亡率高，生命质量较低。而术后免疫治疗可充分调动患者的机体防御机制，激活免疫细胞，杀灭残留癌细胞。目前关于肺癌免疫治疗的研究成果主要包括4大类：过继性免疫治疗、树突状细胞疫苗、非特异性抗原免疫治疗和抗原特异性疫苗。这些研究成果均表明肺癌术后免疫治疗干预可有效减少癌细胞残留，降低术后复发率，延长患者生存时间，显著改善预后，值得临床推广。

关键词: 免疫疗法, 肺肿瘤, 临床试验

Abstract: Surgery in combination with chemotherapy and radiotherapy is the standard of lung cancer treatment, but postoperative recurrence is very common which usually leads to higher mortality and lower life quality. Immunotherapy on postoperative patients fully mobilizes the body′s defense mechanisms, activates the immune cells, and kills residual cancer cells. Current research on lung cancer immunotherapy mainly includes four categories: adoptive immunotherapy, dendritic cell vaccine, nonspecific antigen immune therapy and antigenspecific vaccine.These studies show lung cancer immunotherapy intervention can effectively reduce postoperative residual cancer cells, reduce postoperative recurrence rate, prolong survival, significantly improve the prognosis, and is worth spreading in clinical practice.

Key words: Immunotherapy, Lung neoplasms, Clinical trial